NanoViricides says it is advancing NV-387 toward clinical trials for measles, supported by preclinical findings and existing human safety and Phase II experience in other viral infections.
NanoViricides, Inc. (NYSE American: NNVC) is advancing development of its investigational antiviral NV-387 toward clinical trials for measles. The company is preparing a Phase II study protocol and says the drug remains neither FDA-approved nor commercially available for measles or any other viral disease.
NanoViricides said a draft protocol for evaluating NV-387 as a measles treatment is being circulated. The company intends to submit the protocol to the US FDA through an Investigational New Drug process, adding that this work is expected to take some time.
The company also believes the available data could support physician-initiated investigational use for specific severe cases under the relevant US FDA mechanism. This is not an approval or a commercial authorisation for NV-387.
According to NanoViricides, NV-387 showed strong antiviral activity in a humanized hCD150+, IfnAR-/- mouse model involving measles infection and disease. The company said this result supports continued regulatory development, but it does not establish FDA-evaluated safety or effectiveness for measles treatment.
NV-387 has completed a Phase I human safety study and is currently being evaluated in Phase II trials for Ebola Bundibugyo virus and Mpox in the Democratic Republic of Congo. Both trials use the same oral gummies formulation, according to the company.
NanoViricides also reported results from a repeat-dose juvenile mouse toxicity study. The No Observed Adverse Effect Level was 1,230 mg/kg per dose administered three times daily, or 3,690 mg/kg/day, with total cumulative drug exposure of 44,280 mg/kg over the 12 day dosing period.
The company reported no mortality, systemic toxicity, treatment-related clinical observations, adverse effects on body weight gain, alterations in cardiovascular parameters, changes in clinical pathology, or treatment-related gross or microscopic pathological findings in either sex. Because the highest dose tested produced no such findings, a Maximum Tolerable Dose could not be estimated.
NanoViricides cited 5,164 confirmed measles cases in the USA, excluding international visitors, as of November 5, 2026. The cases had been reported in 47 jurisdictions, with 4% identified as breakthrough cases in vaccinated individuals and 96% in unvaccinated individuals. The company said 562 cases, or 11%, resulted in hospitalisation, while 4 confirmed measles-caused deaths had been recorded.
The company also referred to measles activity in Bangladesh, where it reported 24,073 lab-confirmed cases and 105 fatalities in lab-confirmed cases from 15 March to 10 November, 2026. It said 207,428 patients with suspected measles had been hospitalised during that period and that 1,263 people, mostly children, had died of suspected measles.
NanoViricides said there is currently no approved drug for measles and that vaccination does not treat patients already infected with the virus. It described treatment for measles as an unmet medical need.
The company said the US FDA has granted NV-387 both Orphan Drug Designation and Rare Pediatric Disease Drug Designation for measles treatment. The Rare Pediatric Disease designation may allow eligibility for a Priority Review Voucher if a future marketing application is successful and all required conditions are met.
NanoViricides said the Orphan Drug Designation may provide incentives including tax credits for qualified clinical trials, exemption from certain user fees and potential seven years of market exclusivity after approval. The company also noted that revenue from a measles treatment may be slow and small in a rare disease setting.
The company stated that pharmaceutical development is lengthy and requires substantial capital. It said there is no assurance that NV-387 or its other candidates will demonstrate sufficient effectiveness and safety for human clinical development, obtain regulatory approval or achieve commercialisation and market acceptance.
NanoViricides is developing a Phase II protocol for NV-387 as an investigational measles treatment.
NV-387 is not FDA-approved or commercially available for measles or any other viral disease.
The company reported antiviral activity in a humanized mouse model and results from a juvenile mouse toxicity study.
NV-387 is already in Phase II trials for Ebola Bundibugyo virus and Mpox in the Democratic Republic of Congo.
FDA Orphan Drug and Rare Pediatric Disease designations apply to NV-387 for measles treatment, while any Priority Review Voucher remains conditional on required criteria.
NanoViricides, Inc. announced that it is advancing its measles drug development programme towards clinical trials. The company said it is developing NV-387 as an investigational treatment for measles, but the drug is not yet FDA-approved or commercially available for treating measles or any other viral disease.
NanoViricides, Inc. announced the update on November 10, 2026. The announcement includes measles case and outbreak information covering 2026, including US data reported as of November 5, 2026, and Bangladesh data from 15 March to 10 November, 2026.
NV-387 is NanoViricides, Inc.'s clinical-stage, broad-spectrum antiviral drug candidate. The company says it plans to develop NV-387 as a treatment for measles as well as RSV, COVID, Long COVID, influenza and MPOX/Smallpox infections.
NanoViricides, Inc. says NV-387 demonstrated strong antiviral activity against measles virus in a humanized hCD150+, IfnAR-/- mouse model of measles virus infection and disease. The company describes this preclinical result as supporting the regulatory development of NV-387 for measles treatment, but it does not establish FDA-approved safety or effectiveness.
NanoViricides, Inc. says NV-387 has completed a Phase I human safety study and is currently in Phase II clinical trials for Ebola Bundibugyo virus in the Democratic Republic of Congo and for Mpox in a different province of the Democratic Republic of Congo. Both trials use the same oral gummies formulation, according to the company.
NanoViricides, Inc. says its repeat-dose juvenile mouse toxicity study found a No Observed Adverse Effect Level of 1,230 mg/kg per dose administered three times daily, or 3,690 mg/kg/day, with a total cumulative drug exposure of 44,280 mg/kg over the 12 day dosing period. The company reported no mortality, systemic toxicity, treatment-related clinical observations, adverse effects on body weight gain, alterations in cardiovascular parameters, changes in clinical pathology, or treatment-related gross or microscopic pathological findings in either sex; it also said a Maximum Tolerable Dose could not be estimated because the highest dose level tested produced no such finding.
NanoViricides, Inc. is currently developing a Phase II clinical trial protocol to evaluate NV-387 as a treatment for measles, and the company says a draft is being circulated. It intends to bring the protocol under the purview of the US FDA through an Investigational New Drug process, which the company says is expected to take some time.
NanoViricides, Inc. believes NV-387 has sufficient data to enable use under the US FDA physician-initiated investigational new drug application mechanism for specific severe cases of disease, such as measles. The company also states that NV-387 is not yet FDA-approved or commercially available for treating measles or any other viral disease.
NanoViricides, Inc. says NV-387 has received both Orphan Drug Designation and Rare Pediatric Disease Drug Designation from the US FDA for treatment of measles. The company says the designations may provide incentives including tax credits for qualified clinical trials, exemption from certain user fees, potential seven years of market exclusivity after approval, and eligibility for a Priority Review Voucher if the required conditions are met and a marketing application is successful.
NanoViricides, Inc. says that, in a rare disease scenario, commercial revenue from the drug may be slow and small. The company identifies the Priority Review Voucher as providing additional business value, while stating that such a voucher would depend on a successful marketing application and the required conditions being met.
NanoViricides, Inc. is a clinical-stage company creating special-purpose nanomaterials for antiviral therapy, based on TheraCour nanomedicine technology. The company says its business model is based on licensing technology from TheraCour Pharma, Inc. for specific application verticals of specific viruses, and that it holds broad, exclusive, sub-licensable, field licences to drugs developed in several licensed fields.
NanoViricides, Inc. identifies itself as publicly traded on NYSE American: NNVC. Elsewhere in the announcement, it gives the listing as NYSE-American, stock symbol NNVC.
NanoViricides, Inc. states that pharmaceutical development is lengthy and requires substantial capital, and that there can be no assurance that its candidates will show sufficient effectiveness and safety for human clinical development. The company also identifies risks including preclinical safety and effectiveness, successful development, obtaining regulatory approvals, commercialisation and market acceptance, and says actual events could differ materially from its forward-looking statements.